Top San Francisco Bay Area, CA Biotech Companies (196)
Don't see your company?
Create a company profile
Biotechnology is rewriting life as we know it, from the medicines we take, to the crops we grow, and the household goods that we rely on every day. But moving at the new speed of science requires better technology. Benchling’s mission is to unlock the power of biotechnology. The world’s most innovative biotech companies use Benchling’s R&D Cloud to power the development of breakthrough products. Help us bring modern software to modern science. We’re on Team Science We believe in the promise of science and the teamwork required to fulfill that promise. Whether your background is in science, engineering, business, or another field, you’re on Team Science if you believe in the power of science to solve the world’s most pressing problems.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make near real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Endpoint is an interactive response technology (IRT®) systems and solutions provider that supports the life sciences industry. Since 2009, we have been working with a single vision in mind, to help sponsors and pharmaceutical companies achieve clinical trial success. Our solutions, realized through the proprietary PULSE® platform, have proven to maximize the supply chain, minimize operational costs, and ensure timely and accurate patient dosing. Endpoint is headquartered in Wakefield, Massachusetts with offices across the United States, Europe, and Asia. Endpoint is a subsidiary of Fortrea Holdings, Inc.
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
Cala Health is a bioelectronic medicine company transforming the standard of care for chronic disease. The company’s wearable neuromodulation therapies merge innovations in neuroscience and technology to deliver individualized peripheral nerve stimulation. The first indication for Cala Health’s wearable therapy is essential tremor, a disease experienced by more than seven million people and characterized by severe hand tremors. New therapies are under development in neurology, cardiology, and psychiatry. The company is headquartered in the San Francisco Bay Area and backed by leading investors in both healthcare and technology. #EssentialTremorAwarenessMonth
Trusted by the world's leading organizations, Point B is a consulting firm that works at the intersection of expertise, industry insight, and transformative technology. This collaborative approach enables you to solve your most important challenges, by bringing together the right mix of talent and technology to deliver greater value and impact. With over 850 associates in the US and 3000+ consultants around the world through our Nextcontinent partnership, we work where you do to deliver the change you seek.
Gladstone's mission is to drive a new era of discovery in disease-oriented science and to mentor tomorrow’s leaders in an inspiring and diverse environment. Although Gladstone shares traits with other top life science organizations, we pride ourselves on taking uncommon scientific paths to overcoming disease. Our investigators are selected to become authorities in leading or creating new fields, and we work to provide them with resources to explore bold new thoughts, form effective scientific teams, and create or master emerging research technologies that accelerate progress—Gladstone’s special recipe for success that has yielded some of the most important biomedical advances of our time. Our three disease-focused institutes constitute the core of our discovery engine, but do not operate in isolation. We are seizing unprecedented opportunities for “convergence”—defined as the blending of intellectual and physical assets from multiple scientific disciplines and fields to speed the discovery process in our attack on unsolved health problems that affect almost every human family.
Science is an early stage company developing technologies for a range of serious unmet medical needs. We are unafraid to take difficult technical risks, secure in the knowledge that with a clear understanding of what we are doing and with support from powerful modern tools, more progress is possible than might be immediately obvious.
Lyterian Therapeutics derives its name from the Greek word λυτήριος or lutḗrios, that defines the termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. We are inspired to learn from the logic that orchestrates homeostatic equilibria and fosters healing in response to disease. At Lyterian Therapeutics, we are committed to developing medicines for patients in need by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically validated targets.
We exist to ensure all patients have access to early cardiac and pulmonary disease detection and high quality care that improves and extends their lives. We believe the ability to listen is the ability to care. Which is why we’re dedicated to providing healthcare professionals with industry leading digital tools to hear and understand their patients’ hearts and lungs — allowing them to detect with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Hear clearly. Care confidently.
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
64x Bio is transforming the future of cell and gene therapy manufacturing with high throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, we are developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Proud to be a San Francisco Business Times Best Place to Work in 2021 and 2022, a Great Place to Work-Certified company in 2022 and a part of Fortune's Best Workplaces in the Bay Area in 2022 and Fortune's Best Workplaces in BioPharma in 2022.
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.
We remove atmospheric carbon for a fraction of the cost while increasing crop yields. Our process is highly efficient, increases soil health, and repurposes post-industrial waste. Then we sell the carbon credits to companies and split revenue with our regenerative growers. With a world-class team leveraging expertise in soil chemistry, agronomy, geochemistry, machine learning, and logistics, we are engineering the most cost-effective, and scientifically rigorous solution to enhanced rock weathering at scale. 🌎 🌾 🚜
We help scientists solve disease and extend healthspan by building tools that simplify R&D, simulate biology, and untangle the complexity of life. Streamline computational analysis today. Simulate biology tomorrow.
Talis is developing a new class of diagnostic platform to enable rapid, high-complexity testing across a wide range of healthcare settings. Testing for COVID-19 is in high demand. Learn more about our product options. GenBody COVID-19 Ag Test Minimize disruptions with high-volume SARS-CoV-2 antigen testing and results in 15 minutes Learn more: https://talisbio.com/genbody-covid-19-antigen-test/ TALIS ONE™ COVID-19 TEST SYSTEM Rapid point-of-care COVID-19 test that enables highly sensitive SARS-CoV-2 RNA detection from nasal mid-turbinate swabs in less than 30 minutes. With its dual-gene target design, test sensitivity and inclusivity of variants are optimized. Learn more: https://talisbio.com/talis-one-covid-19-test-system/ Our visionary team combines depth of experience with passion to deliver a pioneering solution to infectious disease diagnostics. Infectious disease treatment today is largely guideline-driven: treat patients with similar symptoms the same. Unfortunately, similar symptoms can often have very different causes. Our tests will enable caregivers to know within minutes, the cause of illness, as well as which medications will be effective for their patient, empowering them to provide individualized care rather than broad, guideline-dictated treatments. From the doctor’s office to the hospital bedside to remote care settings, we are re-defining the treatment of infectious diseases.
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers
Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease
At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Work Your Passion. Live Your Purpose.
